Abstract
Members of the human gut microbiota use glycoside hydrolase (GH) enzymes, such as β-galactosidases, to forage on host mucin glycans and dietary fibres. A human faecal metagenomic fosmid library was constructed and functionally screened to identify novel β-galactosidases. Out of the 16,000 clones screened, 30 β-galactosidase-positive clones were identified. The β-galactosidase gene found in the majority of the clones was BAD_1582 from Bifidobacterium adolescentis, subsequently named bgaC. This gene was cloned with a hexahistidine tag, expressed in Escherichia coli and His-tagged-BgaC was purified using Ni2+-NTA affinity chromatography and size filtration. The enzyme had optimal activity at pH 7.0 and 37 °C, with a wide range of pH (4–10) and temperature (0–40 °C) stability. It required a divalent metal ion co-factor; maximum activity was detected with Mg2+, while Cu2+ and Mn2+ were inhibitory. Kinetic parameters were determined using ortho-nitrophenyl-β-d-galactopyranoside (ONPG) and lactose substrates. BgaC had a Vmax of 107 μmol/min/mg and a Km of 2.5 mM for ONPG and a Vmax of 22 μmol/min/mg and a Km of 3.7 mM for lactose. It exhibited low product inhibition by galactose with a Ki of 116 mM and high tolerance for glucose (66% activity retained in presence of 700 mM glucose). In addition, BgaC possessed transglycosylation activity to produce galactooligosaccharides (GOS) from lactose, as determined by TLC and HPLC analysis. The enzymatic characteristics of B. adolescentis BgaC make it an ideal candidate for dairy industry applications and prebiotic manufacture. Key points • Bifidobacterium adolescentis BgaC β-galactosidase was selected from human faecal metagenome. • BgaC possesses sought-after properties for biotechnology, e.g. low product inhibition. • BgaC has transglycosylation activity producing prebiotic oligosaccharides. [Figure not available: see fulltext.]
Original language | English |
---|---|
Pages (from-to) | 1063-1078 |
Number of pages | 16 |
Journal | Applied Microbiology and Biotechnology |
Volume | 105 |
Issue number | 3 |
Early online date | 11 Jan 2021 |
DOIs | |
Publication status | Published - 28 Feb 2021 |
Bibliographical note
Funding Information:We thank technical staff members Ms. Ann Smyth, Dr. Katrina Lacey, Mr. Mike Coughlan and Mr. Maurice Martyn, Discipline of Microbiology, NUI Galway, for the technical support. We are grateful to Dr. Maria Tuohy (NUI Galway) for providing access to instruments. We thank Glycom A/S, H?rsholm, Denmark, for kindly providing the HMOs used in this study.
Funding Information:
DMM was supported by a NUI Galway College of Science PhD scholarship. CA was supported by the PhD programme “Molecular and Cellular Mechanisms Underlying Inflammatory Processes” funded by the Higher Education Authority of Ireland under Cycle 5 of the Irish Government’s Programme for Research in Third Level Institutions (PRTLI).
Publisher Copyright:
© 2021, The Author(s).
Funding
DMM was supported by a NUI Galway College of Science PhD scholarship. CA was supported by the PhD programme “Molecular and Cellular Mechanisms Underlying Inflammatory Processes” funded by the Higher Education Authority of Ireland under Cycle 5 of the Irish Government’s Programme for Research in Third Level Institutions (PRTLI).
Keywords
- Bifidobacterium
- Enzyme screening
- Metagenomic library
- Transglycosylation
- β-Galactosidase
ASJC Scopus subject areas
- Biotechnology
- Applied Microbiology and Biotechnology